---
figid: PMC6282975__MDS-33-684-g001
figtitle: Potential mechanisms for genetic‐based investigational therapies for Parkinson's
  disease targeting A‐synuclein (SNCA), glucocerebrosidase (GBA), and leucine‐rich
  repeat kinase (LRRK2)
organisms:
- Adeno-associated virus
- Adeno-associated virus - 1
- Homo sapiens
- Mus musculus
- Caenorhabditis elegans
- Triticum aestivum
- prion
pmcid: PMC6282975
filename: MDS-33-684-g001.jpg
figlink: /pmc/articles/PMC6282975/figure/mds27414-fig-0001/
number: F1
caption: 'Potential mechanisms for genetic‐based investigational therapies for Parkinson''s
  disease targeting α‐synuclein (SNCA), glucocerebrosidase (GBA), and leucine‐rich
  repeat kinase (LRRK2). Targeting SNCA: (1) reducing α‐synuclein production, (2)
  decreasing α‐synuclein aggregation, (3) enhancing autophagy, (4) reducing availability
  of extracellular aggregates, (5) inhibiting cellular uptake of α‐synuclein. Targeting
  the GBA pathway: (6) increasing glucocerebrosidase (GCase) activity, (7) modulating
  GBA‐related glycosphingolipids. Targeting LRRK2: (8) LRRK2 kinase inhibitors.'
papertitle: 'Targeted Therapies for Parkinson''s Disease: From Genetics to the Clinic.'
reftext: S. Pablo Sardi, et al. Mov Disord. 2018 May;33(5):684-696.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6620203
figid_alias: PMC6282975__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC6282975__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6282975__MDS-33-684-g001.html
  '@type': Dataset
  description: 'Potential mechanisms for genetic‐based investigational therapies for
    Parkinson''s disease targeting α‐synuclein (SNCA), glucocerebrosidase (GBA), and
    leucine‐rich repeat kinase (LRRK2). Targeting SNCA: (1) reducing α‐synuclein production,
    (2) decreasing α‐synuclein aggregation, (3) enhancing autophagy, (4) reducing
    availability of extracellular aggregates, (5) inhibiting cellular uptake of α‐synuclein.
    Targeting the GBA pathway: (6) increasing glucocerebrosidase (GCase) activity,
    (7) modulating GBA‐related glycosphingolipids. Targeting LRRK2: (8) LRRK2 kinase
    inhibitors.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Snca
  - Gba1
  - Lrrk2
  - GCLC
  - UGCG
  - GOLGA4
  - LRRK2
  - Cs
  - CS
  - UDP
  - O
---
